3 Stocks Advancing The Drugs Industry

TheStreet highlights 3 stocks pushing the health services industry higher today.
By TheStreet Wire ,

Two out of the three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 71 points (0.4%) at 17,316 as of Monday, Nov. 16, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,543 issues advancing vs. 1,341 declining with 209 unchanged.

The Drugs industry currently sits down 2.2% versus the S&P 500, which is up 0.2%. Top gainers within the industry include

AstraZeneca

(

AZN

), up 3.9%, and

Novartis

(

NVS

), up 0.6%. On the negative front, top decliners within the industry include

ISIS Pharmaceuticals

(

ISIS

), down 4.4%,

Medivation

(

MDVN

), down 4.3%,

Incyte

(

INCY

), down 1.4% and

Gilead

(

GILD

), down 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Abbott Laboratories

(

ABT

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.30 (0.7%) to $44.26 on light volume. Thus far, 1.9 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.7 million shares. The stock has ranged in price between $43.80-$44.56 after having opened the day at $43.81 as compared to the previous trading day's close of $43.96.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abbott Laboratories manufactures and sells health care products worldwide. Abbott Laboratories has a market cap of $65.9 billion and is part of the health care sector. Shares are down 2.4% year-to-date as of the close of trading on Friday. Currently there are 12 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Abbott Laboratories

as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Abbott Laboratories Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Mylan

(

MYL

) is up $0.74 (1.5%) to $49.52 on average volume. Thus far, 3.9 million shares of Mylan exchanged hands as compared to its average daily volume of 8.4 million shares. The stock has ranged in price between $48.40-$49.88 after having opened the day at $48.86 as compared to the previous trading day's close of $48.78.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. Mylan has a market cap of $21.2 billion and is part of the health care sector. Shares are down 13.5% year-to-date as of the close of trading on Friday. Currently there are 4 analysts who rate Mylan a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Mylan

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Mylan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Eli Lilly and

(

LLY

) is up $1.03 (1.3%) to $80.58 on light volume. Thus far, 1.2 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 5.8 million shares. The stock has ranged in price between $79.98-$81.05 after having opened the day at $79.98 as compared to the previous trading day's close of $79.55.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $88.5 billion and is part of the health care sector. Shares are up 15.3% year-to-date as of the close of trading on Friday. Currently there are 7 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Eli Lilly and

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Eli Lilly and Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...